These antimicrobial peptides (AMPs) have been engineered to enhance their potency against drug-resistant microbial infections.
Description
The peptides exhibit broad-spectrum antimicrobial activity, substantial anti-biofilm properties, and superior safety profiles compared to existing antibiotics like colistin. This innovation holds significant potential for addressing the growing challenge of antibiotic resistance.
Applications
• Drug-Resistant Infections
• Sepsis
• Respiratory Infections
• Wound Care
Advantages
Unlike traditional small molecule antibiotics, these peptides are designed to enhance antimicrobial activity through increased cationic content and optimized amphipathicity. This results in superior potency against multidrug-resistant bacteria, including those that thrive in high salt and acidic environments. The peptides also exhibit significant anti-biofilm properties, making them effective in treating persistent infections. Additionally, their low cytotoxicity and systemic safety profile surpass that of colistin, a last-resort antibiotic. These features make the peptides a promising alternative for treating drug-resistant infections, potentially reducing the reliance on existing antibiotics and mitigating the risk of resistance development.
Invention Readiness
The invention is currently at the in vivo testing stage, with promising results demonstrating strong antimicrobial activity and safety in animal models. The peptides have shown efficacy in both respiratory and septicemic models of Pseudomonas aeruginosa infections. Further development steps include scaling up production, conducting comprehensive preclinical studies, and initiating clinical trials to validate the peptides’ efficacy and safety in humans. The next phase will focus on optimizing the formulation and delivery methods to enhance therapeutic outcomes and ensure regulatory compliance.
IP Status
https://patents.google.com/patent/US11965006B2
